Salute e Benessere
Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight
Discover the urothelial carcinoma new treatment @
The urothelial carcinoma market dynamics are expected to change in the coming years. , along with various R&D practices, are enabling the development of the urothelial carcinoma market, where drug combination therapies offer more effective disease control. The , used either as monotherapy or in combination, is further driving market growth. Additionally, the in bladder and upper urinary tract cancers over the past decade underscores the importance of germline testing in guiding treatment decisions. As a result, increasingly rely on such tools to identify patients who may benefit from targeted therapies.
As potential therapies are being investigated for the treatment of urothelial carcinoma, it is safe to predict that the treatment space will significantly impact the urothelial carcinoma market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the urothelial carcinoma market in the 7MM.
However, several factors may impede the growth of the urothelial carcinoma market. Around of patients with metastatic urothelial cancer are due to comorbidities, highlighting a significant unmet need for tolerable therapies that can extend survival in older, frail populations. Additionally, up to within a year post-surgery, with no effective measures currently available to prevent it, leaving many patients fearful of relapse. This underscores the in the adjuvant setting, where novel approaches such as cancer vaccines are emerging as potential competitors to traditional therapies like chemotherapy.
Moreover, urothelial carcinoma treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the urothelial carcinoma market growth may be offset by , , , and a . In addition, the about the disease may also impact the Urothelial Carcinoma market growth.
The current management of urothelial carcinoma relies on a comprehensive, multimodal strategy. For non-muscle invasive disease, surgical procedures such as Transurethral Resection (TUR) are commonly used for diagnosis, staging, and initial control. In more advanced or recurrent cases, repeat TUR or radical cystectomy may be warranted.
For patients with locally advanced or metastatic urothelial carcinoma, cisplatin-based chemotherapy remains the standard first-line therapy. However, targeted treatments such as FGFR inhibitors and immune checkpoint inhibitors (targeting PD-1/PD-L1) have emerged as valuable alternatives, especially for individuals with specific genetic alterations or treatment-resistant disease.
Several pharmaceutical companies are at the forefront of this therapeutic area, including .
PADCEV (enfortumab vedotin-ejfv) is a pioneering Antibody-Drug Conjugate (ADC) that targets Nectin-4, a cell surface protein abundantly expressed in bladder cancer. Preclinical studies indicate that PADCEV exerts its anti-tumor effects by binding to Nectin-4-positive cells, leading to internalization and release of the cytotoxic agent Monomethyl Auristatin E (MMAE). This results in cell cycle arrest and apoptosis.
PADCEV received FDA approval in December 2019 for patients with locally advanced or metastatic urothelial cancer who had previously been treated with both a PD-1/PD-L1 inhibitor and platinum-based chemotherapy, either before or after surgery or in the metastatic setting. In April 2023 , the FDA further approved the combination of PADCEV with KEYTRUDA for patients ineligible for cisplatin-containing regimens.
OPDIVO, an immune checkpoint inhibitor targeting the PD-1 receptor, enhances T-cell activity against tumor cells, thereby acting as a powerful immunotherapeutic agent. Its clinical utility includes indications, mechanism of action, dosing protocols, and known side effects, especially relevant to clinicians treating metastatic melanoma and similar cancers.
In August 2021 , OPDIVO was approved by the FDA as an adjuvant therapy for patients with high-risk urothelial carcinoma following radical surgery. Most recently, in March 2024 , it received approval in combination with cisplatin and gemcitabine as a first-line treatment for adults with unresectable or metastatic urothelial carcinoma.
To know more about FDA-approved drugs for urothelial carcinoma, visit @
The urothelial carcinoma pipeline seems to be quite strong. The most promising ones include by UroGen Pharma, by Acrivon Therapeutics, and by Tyra Biosciences.
is a novel mitomycin-based therapy being developed by UroGen for the treatment of low-grade upper tract urothelial carcinoma. Leveraging UroGen's RTGel® technology it allows for extended exposure to mitomycin, potentially enabling effective, non-surgical treatment. The drug is currently undergoing Phase III trials and benefits from similar intellectual property protections.
Meanwhile, is an experimental FGFR3 inhibitor engineered to be both highly potent and selective. It is specifically designed to overcome key challenges associated with existing FGFR-targeted therapies, such as resistance due to mutations like the V555 gatekeeper mutation, and to minimize off-target effects by favoring FGFR3 over FGFR1 and other FGFR isoforms. TYRA-300 is under Phase I/II clinical evaluation for advanced urothelial carcinoma, and in February 2024 , it received the FDA's Rare Pediatric Disease (RPD) designation.
The anticipated launch of these emerging therapies are poised to transform the urothelial carcinoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the urothelial carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about urothelial carcinoma marketed and pipeline drugs @
Urothelial carcinoma exhibits a wide range of clinical behaviors. On the less severe end, it can appear as low-grade, non-muscle-invasive disease, typically not life-threatening but characterized by frequent recurrence and requiring ongoing monitoring. On the more severe end, the cancer may be high-grade, either non-muscle-invasive or muscle-invasive, both associated with a significantly elevated risk profile. Muscle-invasive bladder cancer (MIBC) is a serious condition that requires immediate intervention, while high-grade non-muscle-invasive forms have a substantial likelihood of advancing to muscle-invasive or metastatic disease, often resulting in poor prognosis. The chances of metastasis increase with tumor stage, about 25% in pT2, 50% in pT3, and 80% in pT4, correlating with five-year survival rates of 67%, 35%, and 27%, respectively. Due to the disease's heterogeneity, particularly in intermediate cases, standard treatment strategies may be ineffective for roughly one-quarter of patients.
Urine cytology is the most commonly used noninvasive method for detecting urothelial tumors, though its sensitivity is limited. Cystoscopy, while considered the gold standard for follow-up in bladder cancer patients, is invasive and expensive. Biomarker-based tests such as Bladder Tumor Antigen (BTA) stat, BTA TRAK, Nuclear Matrix Protein 22 (NMP-22), ImmunoCyt/uCyt, and UroVysion have received FDA clearance or approval as alternative diagnostic tools. However, the U.S. Preventive Services Task Force advises against routine bladder cancer screening in adults, as current noninvasive urine tests, despite their ability to identify the disease in asymptomatic individuals, offer low positive predictive value and have not been shown to improve long-term outcomes. Imaging studies of the urinary tract help determine tumor location, assess disease extent, and identify multifocal involvement. Computed tomography (CT) has largely replaced intravenous pyelography (IVP) due to its simplicity and noninvasive nature.
The urothelial carcinoma epidemiology section provides insights into the historical and current urothelial carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The urothelial carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving urothelial carcinoma treatment market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key urothelial carcinoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic urothelial carcinoma companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic urothelial carcinoma companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced urothelial carcinoma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/urothelial-carcinoma-market-set-to-expand-during-the-forecast-period-20252034-amid-rising-incidence-and-evolving-therapeutic-landscape--delveinsight-302522860.html